NEW YORK, February 23, 2017 /PRNewswire/ --
Today's attention is directed to the Biotech industry which has startedposting gains again after a loss of more than 20% in 2016. According to an article on Seeking Alpha, the rally is likely to continue, as the biggest play in the sector, the iShares Nasdaq Biotechnology ETF, is up by more than 10% on the year, whereas
Seattle, Washington headquartered Juno Therapeutics Inc.'s shares saw a slight decline of 0.17%, finishing Wednesday's trading session at $23.05. A total volume of 1.44 million shares was traded. In the last one month and since the start of this year, the stock has advanced 17.84% and 22.28%, respectively. The Company's shares are trading above their 50-day moving average by 14.60%. Moreover, shares of Juno Therapeutics, which engages in developing cell-based cancer immunotherapies, have a Relative Strength Index (RSI) of 64.68.
On February 22nd, 2017, Juno Therapeutics announced that it will report financial results for Q4 2016 and full year 2016, on March 01st, 2017, after the close of US-based financial markets. Following the announcement, Juno's management will host a conference call to provide a business update and discuss financial results beginning at 2:00 p.m. PT.
Yesterday, research firm Wells Fargo initiated an 'Outperform' rating on the Company's stock. See our free and comprehensive research report on JUNO at: http://stock-callers.com/registration/?symbol=JUNO
On Wednesday, shares in Carmiel, Israel-based Protalix BioTherapeutics Inc. recorded a trading volume of 2.29 million shares, and ended the session 0.94% lower at $1.05. The stock has surged 105.88% in the last one month, 114.29% in the previous three months, and 133.33% on an YTD basis. The Company's shares are trading 82.80% and 72.91% above their 50-day and 200-day moving averages, respectively. Furthermore, shares of Protalix BioTherapeutics, which focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally, have an RSI of 66.67.
On February 15th, 2017, Protalix BioTherapeutics announced that its board of directors approved the record date for the Company's 2017 Annual Meeting of Stockholders to be held on or about April 10th, 2017. Holders of the Company's common stock at the close of business on March 15th, 2017, the record date, will be entitled to receive notice of, and to vote at, the Annual Meeting. PLX free research report PDF is just a click away at: http://stock-callers.com/registration/?symbol=PLX
Shares in Waltham, Massachusetts headquartered ImmunoGen Inc. closed the day flat at $2.47 with a total trading volume of 861,718 shares. The stock has gained 19.32% in the previous three months and 21.08% since the start of this year. The Company's shares are trading 12.17% above their 50-day moving average. Additionally, shares of ImmunoGen, which develops targeted anticancer therapeutics, have an RSI of 60.89.
On February 17th, 2017, ImmunoGen reported revenues for the six month transition period ended December 31st, 2016, of $21.5 million compared to $32.9 million for the six months ended December 31st, 2015. ImmunoGen reported a net loss of $78.9 million, or $0.91 per basic and diluted share, for the Company's six month fiscal year transition period ended December 31st, 2016, compared to a net loss of $67.0 million, or $0.77 per basic and diluted share, for the same period last year. ImmunoGen had approximately $160.0 million in cash and cash equivalents as of December 31st, 2016. Sign up for your complimentary report on IMGN at: http://stock-callers.com/registration/?symbol=IMGN
At the closing bell yesterday, shares in Edison, New Jersey headquartered ContraVir Pharmaceuticals Inc. ended flat at $1.53 with a total trading volume of 334,364 shares. The stock has advanced 7.75% in the last one month and 27.50% on an YTD basis. The Company's shares are trading above their 50-day and 200-day moving averages by 1.21% and 13.86%, respectively. Furthermore, shares of ContraVir Pharma, which operates as a biopharmaceutical company focused on the development of antiviral drugs with a primary emphasis on the treatment of Hepatitis B virus infections, have an RSI of 54.74.
On January 03rd, 2017, ContraVir announced that the Company was awarded a $297,875 CAD research grant from the National Research Council in Canada through the Council's Industrial Research Assistance Program. Proceeds from the grant will fund a substantial portion of personnel expenses, including the hiring of additional laboratory staff, which is expected to advance preclinical development of ContraVir's potent cyclophilin inhibitor CRV431 for the Treatment of Hepatitis B. Register for free on Stock-Callers.com and download the latest research report on CTRV at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: firstname.lastname@example.org Phone number: +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
HELLP syndrome is a rare but serious complication that affects pregnant women. If detected on time, ...
Discectomy is a surgical procedure in which a herniated (bulged) disc that compresses the nerves of ...
Parotidectomy is a surgery to remove a part of or the entire parotid salivary gland, on the side of ...View All